# Targeted inhibition of FBXL2 confers susceptibility of HER2-negative breast cancer to trastuzumab deruxtecan

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/targeted-inhibition-of-fbxl2-confers-susceptibility-of-her2-negative-breast/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Jing Xu,Jiayi Liu,Yang Liu,Ting Huang,Yong Yi,Ruixiao Bai,Haorui Zheng,Xiaoli Chen,Jiexin Gao,Xin Lian,Rongtian Guo,Chuan Xu,Qintong Li,Y. Zhang,Yang Cao,Peng Mi,Zhi-Xiong Jim Xiao,MengMeng Niu |
| Citations | 1 |
| DOI | 10.1038/s43018-025-01112-z |
| Fields | Biochemistry, Genetics and Molecular Biology,Chemistry,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W7126062401 |
| PMID | 41612000 |
| Type | article |
| Year | 2026 |

## Paper authors

- [Y. Zhang](https://scholariq.org/researchers/y-zhang/)

## Paper primary topic

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

## Paper topics

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Click Chemistry and Applications](https://scholariq.org/topics/click-chemistry-and-applications/)
- [Ubiquitin and proteasome pathways](https://scholariq.org/topics/ubiquitin-and-proteasome-pathways/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.